Eli Lilly

Lilly controls the peptide-manufacturing + molecule-efficacy bottleneck of the GLP-1/incretin class. Q2 2026 volume grew +60% while realized price fell −13% — growth is purely capacity-led, proving the binding constraint is how much injectable peptide Lilly can physically make, not how many patients want it. Mounjaro + Zepbound alone generated $27.7B in H1 2026 (64.8% of total revenue), an annualized ~$55B run-rate for a single molecule. The manufacturing moat (solid-phase peptide synthesis at multi-metric-ton scale, fill-finish, ~5-year facility lead times) is the irreplaceable friction — a competitor can discover a peptide in a lab in years, but cannot replicate Lilly's ~$30B+ of qualified capacity without a half-decade of capex and FDA re-validation.

• Q1 BYPASS = 2 (PARTIAL): Novo Nordisk's semaglutide (~15% mean weight loss) is an approved, reimbursed substitute at the ~15% efficacy tier, so Lilly's incretin franchise is a duopoly on efficacy, not a pure monopoly. The efficacy gap is the switching cost: retatrutide ~28.3% ≈ 1.9× semaglutide, tirzepatide ~21% ≈ 1.4×. Switching a patient off Lilly's superior molecule forfeits the efficacy advantage → "substitutes exist, but switching cost is high" (PARTIAL, not PASS).
• Q2 CONCENTRATION = 3 (PASS): Lilly + Novo ≈ ~90% of the GLP-1 market. Q2 2026 gross margin 85.8% (+1.5pp YoY) far clears the ≥65% pricing-power bar. Demonstrated pricing power despite −13% realized price (China NRDL mandated cuts + US rebates — geography/mix, not competitive erosion).
• Q3 HYPERSCALER = 3 (PASS): No hyperscaler-equivalent (big tech / China genomics) has an announced GLP-1 therapeutic. Compounding pharmacies are a gray-market threat Lilly is actively litigating — not a bundled "good-enough + free" GA product. The Intervene layer faces no BGI/MGI-style structural commoditizer (that threat is confined to HS Measure/Read).

Composite: 2 + 3 + 3 = 8 → DIRECT BOTTLENECK (Tier 1). One PARTIAL (duopoly bypass) caps it below 9, consistent with the note's technical_scarcity=8.

• product_service: Branded prescription biopharmaceuticals, led by tirzepatide (Mounjaro/Zepbound), oncology, immunology, and diabetes. (FY2024 10-K Item 1)
• technical function: Small molecules/biologics modulating disease pathways; tirzepatide is a dual GIP/GLP-1 receptor agonist. (FY2024 10-K Item 1)
• why it is hard: Multi-year trials, FDA/global approvals, complex manufacturing/cold chain, scale-up, and patent/exclusivity protection. (FY2024 10-K Item 1, Item 1A Risk Factors)
• substitutes: Other GLP-1/GIP therapies (semaglutide), insulin, oral antidiabetics, bariatric surgery; other oncology/immunology drugs. (FY2024 10-K Item 1A)
• pricing power: HIGH — differentiated tirzepatide franchise with supply-constrained demand; offset by payer rebates/Medicare negotiation. (FY2024 10-K Item 1, Item 1A)

• Exact tirzepatide composition-of-matter patent expiry and retatrutide patent estate — not yet confirmed from a primary patent source (open question).
• Retatrutide head-to-head vs tirzepatide (not yet reported) — the franchise's internal cannibalization rate.
• Whether the −13% realized-price trend stabilizes or deepens as China NRDL and US rebates fully annualize.

• CagriSema FDA decision Q4 2026 — exact PDUFA date and final label (needs FDA-docket confirmation).
• Whether retatrutide's 28.3% (80wk) holds at population scale once the BMJ meta-analysis can grade it at higher certainty.
• Whether tirzepatide + eloralintide (~25.5%/24wk) is Lilly's intended retatrutide complement or successor.

STRENGTHENED — Q2 2026 (+48% revenue, +60% volume) confirms the capacity-led growth thesis; retatrutide's completed Phase 3 package (~28.3% loss, no plateau) extends the efficacy moat into the late-2020s; the $4.5B incremental Indiana commitment proves Lilly is converting free cash flow into an unreplicable physical moat. The only real risks are price erosion and oral commoditization, neither of which breaks the thesis in a 6–24 month window.